← Leaderboards
Chad Edward Beyer
Promentis Pharmaceuticals, Inc.
$975,683
Attributed
$1,951,366
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $600K · FY2012–15$1M$750K$500K$250K$0
'12
'13
'14
'15
Funding mix
By agency
NIH$1,951,366 · 2
By mechanism
R44$1,800,000 · 1
R43$151,366 · 1
Top collaborators
- David A Baker3 shared
- Joseph D. Buxbaum1 shared
Most similar at Promentis Pharmaceuticals, Inc.
Same institution · by research overlap
- Steven R Pollock$169,456
Others in their field
Top investigators on “Pre-Clinical”
- Leonard Freedman · Leidos Biomedical Research, Inc.$264,541,531
- Dennis R. Burton · Scripps Research Institute$257,157,696
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$212,820,795
- Barton F Haynes · Duke University$186,001,832
- David Heimbrook · Leidos Biomedical Research, Inc.$151,740,590
- Reisa A. Sperling · Banner Health$137,047,788
Research focus
Pre-ClinicalPropertyGlutamatesPharmaceutical PreparationsCystineProdrugsDrug KineticsFunctional DisorderIn VitroMental DisordersCostCysteineDesignDrug DesignBehaviorAdverse EffectsExtracellularCaringBrainAcetylcysteineLeadMeetingsAffectQuality Of Life
Grant awards (4)
Targeting System Xc- for the treatment of the Autism Spectrum Disorder subpopulations, Fragile X syndrome and Phelan-McDermid syndrome$151,366
R43 · FY2015 · HD · contact PI
Targeting System Xc- for the Treatment of Schizophrenia$600,000
R44 · FY2014 · MH · contact PI
Targeting System Xc- for the Treatment of Schizophrenia$600,000
R44 · FY2013 · MH · contact PI
Targeting System Xc- for the Treatment of Schizophrenia$600,000
R44 · FY2012 · MH · contact PI